Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

(2020) Victor M Corman et al.   Eurosurveillance

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

(2020) Yixuan J. Hou et al.   CELL

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

(2020) Daniel Blanco-Melo et al.   CELL

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

(2020) Carly G.K. Ziegler et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19

(2020) Annsea Park et al.   Cell Host & Microbe

Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract

(2020) Joan C. Smith et al.   DEVELOPMENTAL CELL

SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells

(2020) Soeren Lukassen et al.   EMBO JOURNAL

Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults

(2020) Supinda Bunyavanich et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Knowledge synthesis of 100 million biomedical documents augments the deep expression profiling of coronavirus receptors

(2020) AJ Venkatakrishnan et al.   eLife

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

(2020) Nan Wang et al.   Cell Host & Microbe

Inhibition of SARS-CoV-2 by type I and type III interferons

(2020) Ulrike Felgenhauer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19

(2020) Bruna G G Pinto et al.   JOURNAL OF INFECTIOUS DISEASES

Increasing host cellular receptor—angiotensin‐converting enzyme 2 expression by coronavirus may facilitate 2019‐nCoV (or SARS‐CoV‐2) infection

(2020) Meng‐Wei Zhuang et al.   JOURNAL OF MEDICAL VIROLOGY

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

(2020) Abigail Vanderheiden et al.   JOURNAL OF VIROLOGY

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

(2020) Megan L. Stanifer et al.   Cell Reports

Shared and Distinct Functions of Type I and Type III Interferons

(2019) Helen M. Lazear et al.   IMMUNITY

IFN-λ prevents influenza virus spread from the upper airways to the lungs and limits virus transmission

(2018) Jonas Klinkhammer et al.   eLife

IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment

(2016) Sophia Davidson et al.   EMBO Molecular Medicine